IXHL News & Events

Incannex Healthcare announced the appointment of three additional members to its recently established Clinical Advisory Board: Murray Stein, MD, MPH; Andrew Cutler, MD; and Amir Kalali, MD. The CAB was formed to provide independent clinical and scientific guidance as the Company progresses PSX-001 into its next phase of clinical and regulatory development. Among its roles, the CAB will advise Incannex on clinical trial design, endpoint selection, regulatory engagement, and broader development strategy as PSX-001 advances.

Incannex Healthcare announces the formation of a Clinical Advisory Board, CAB, to support the continued advancement of its PSX-001 development program in generalized anxiety disorder. The newly established CAB has been formed to provide independent clinical and scientific guidance as the Company progresses PSX-001 into its next phase of clinical and regulatory development. The CAB will advise Incannex on clinical trial design, endpoint selection, regulatory engagement, and broader strategic approach for PSX-001 as the program advances.